 Rebecca Schweppe
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 22 | 2023 | 271 | 7.540 |
Why?
| | Proto-Oncogene Proteins B-raf | 10 | 2023 | 191 | 3.110 |
Why?
| | Thyroid Carcinoma, Anaplastic | 5 | 2023 | 34 | 2.430 |
Why?
| | src-Family Kinases | 4 | 2023 | 88 | 2.300 |
Why?
| | MAP Kinase Signaling System | 4 | 2023 | 271 | 1.550 |
Why?
| | Adenocarcinoma, Follicular | 4 | 2019 | 34 | 1.460 |
Why?
| | Focal Adhesion Kinase 1 | 4 | 2018 | 27 | 1.380 |
Why?
| | Dasatinib | 5 | 2023 | 45 | 1.200 |
Why?
| | Mutation | 10 | 2019 | 3338 | 1.080 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2021 | 66 | 1.060 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 2698 | 1.040 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 636 | 0.950 |
Why?
| | Cell Culture Techniques | 4 | 2019 | 341 | 0.820 |
Why?
| | Protein Kinase Inhibitors | 6 | 2023 | 784 | 0.820 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 33 | 0.750 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.740 |
Why?
| | Neoplasm Transplantation | 5 | 2019 | 227 | 0.720 |
Why?
| | DNA, Neoplasm | 2 | 2013 | 155 | 0.700 |
Why?
| | Carcinoma | 3 | 2009 | 198 | 0.650 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 5 | 0.640 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 47 | 0.620 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 228 | 0.620 |
Why?
| | Thyroid Diseases | 1 | 2018 | 31 | 0.620 |
Why?
| | Ethics, Research | 1 | 2018 | 32 | 0.610 |
Why?
| | Melanoma | 3 | 2021 | 620 | 0.590 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 385 | 0.590 |
Why?
| | Neoplasm Metastasis | 4 | 2016 | 521 | 0.580 |
Why?
| | Prolactin | 4 | 2003 | 96 | 0.580 |
Why?
| | Endocrinology | 1 | 2018 | 71 | 0.580 |
Why?
| | Telomerase | 2 | 2019 | 205 | 0.570 |
Why?
| | Mice, Nude | 7 | 2021 | 628 | 0.570 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 176 | 0.560 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 1875 | 0.540 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2019 | 393 | 0.530 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 445 | 0.490 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1519 | 0.490 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1032 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 1880 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1356 | 0.440 |
Why?
| | Disease Models, Animal | 4 | 2019 | 3498 | 0.420 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 74 | 0.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1142 | 0.420 |
Why?
| | Cell Proliferation | 7 | 2021 | 2173 | 0.400 |
Why?
| | Thiazoles | 1 | 2012 | 110 | 0.380 |
Why?
| | DNA-Binding Proteins | 6 | 2014 | 1311 | 0.370 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 695 | 0.350 |
Why?
| | Humans | 32 | 2023 | 114043 | 0.350 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1846 | 0.340 |
Why?
| | Bone Neoplasms | 1 | 2012 | 191 | 0.340 |
Why?
| | Promoter Regions, Genetic | 6 | 2018 | 1131 | 0.340 |
Why?
| | Animals | 19 | 2021 | 31565 | 0.340 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 27 | 0.330 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 845 | 0.330 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 11 | 0.320 |
Why?
| | Pyrimidines | 1 | 2012 | 374 | 0.320 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 27 | 0.320 |
Why?
| | Iodine Radioisotopes | 2 | 2023 | 126 | 0.320 |
Why?
| | Mice | 10 | 2021 | 14841 | 0.310 |
Why?
| | Protein Processing, Post-Translational | 3 | 2012 | 399 | 0.310 |
Why?
| | Signal Transduction | 8 | 2018 | 4501 | 0.300 |
Why?
| | Cell Differentiation | 2 | 2014 | 1695 | 0.300 |
Why?
| | Benzodioxoles | 1 | 2009 | 83 | 0.300 |
Why?
| | Transcription Factors | 5 | 2014 | 1525 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 3 | 2003 | 607 | 0.300 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 164 | 0.300 |
Why?
| | Apoptosis | 4 | 2021 | 2349 | 0.280 |
Why?
| | Quinazolines | 1 | 2009 | 240 | 0.280 |
Why?
| | Cell Line | 5 | 2019 | 2629 | 0.280 |
Why?
| | Heterografts | 3 | 2016 | 117 | 0.270 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 15 | 0.270 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 145 | 0.250 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 270 | 0.240 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 250 | 0.230 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 24 | 0.220 |
Why?
| | Phenotype | 2 | 2023 | 2784 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 76 | 0.210 |
Why?
| | Fibronectins | 1 | 2023 | 108 | 0.210 |
Why?
| | Models, Biological | 2 | 2020 | 1611 | 0.200 |
Why?
| | Phosphorylation | 7 | 2015 | 1558 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 397 | 0.190 |
Why?
| | Mass Spectrometry | 2 | 2009 | 622 | 0.190 |
Why?
| | Aminopyridines | 1 | 2021 | 81 | 0.180 |
Why?
| | Pyrimidinones | 1 | 2021 | 88 | 0.180 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2020 | 157 | 0.180 |
Why?
| | Proteins | 2 | 2003 | 906 | 0.180 |
Why?
| | Pyridones | 1 | 2021 | 122 | 0.170 |
Why?
| | Pyrroles | 1 | 2021 | 181 | 0.170 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 23 | 0.160 |
Why?
| | Piperazines | 1 | 2021 | 310 | 0.160 |
Why?
| | Ethics, Professional | 1 | 2018 | 14 | 0.160 |
Why?
| | Ethics Consultation | 1 | 2018 | 6 | 0.160 |
Why?
| | Professional Misconduct | 1 | 2018 | 11 | 0.160 |
Why?
| | NF-kappa B | 2 | 2014 | 636 | 0.150 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 38 | 0.150 |
Why?
| | Publications | 1 | 2018 | 37 | 0.150 |
Why?
| | Pyridines | 1 | 2021 | 419 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.150 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 39 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2006 | 2321 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 32 | 0.150 |
Why?
| | Genomics | 2 | 2020 | 633 | 0.150 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 30 | 0.140 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 82 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 48 | 0.140 |
Why?
| | Adrenocortical Carcinoma | 1 | 2018 | 47 | 0.140 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 162 | 0.130 |
Why?
| | Cell Growth Processes | 1 | 2016 | 51 | 0.130 |
Why?
| | Genes, ras | 1 | 2016 | 91 | 0.130 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 53 | 0.130 |
Why?
| | Female | 6 | 2021 | 59325 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2018 | 405 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 556 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 437 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-yes | 1 | 2015 | 2 | 0.120 |
Why?
| | Databases, Genetic | 1 | 2016 | 206 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2016 | 175 | 0.120 |
Why?
| | Cell Death | 1 | 2016 | 322 | 0.120 |
Why?
| | Heart Neoplasms | 1 | 2015 | 49 | 0.120 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2014 | 8 | 0.110 |
Why?
| | Thyroid Gland | 1 | 2014 | 85 | 0.110 |
Why?
| | Data Collection | 1 | 2016 | 618 | 0.110 |
Why?
| | Binding Sites | 3 | 2003 | 1166 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 229 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 868 | 0.110 |
Why?
| | Sirolimus | 1 | 2014 | 181 | 0.100 |
Why?
| | GA-Binding Protein Transcription Factor | 2 | 2003 | 5 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 280 | 0.100 |
Why?
| | Nitriles | 2 | 2010 | 149 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 84 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2009 | 159 | 0.100 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 3 | 2003 | 18 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-ets | 3 | 2003 | 51 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 359 | 0.090 |
Why?
| | Protein Binding | 3 | 2009 | 1888 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 258 | 0.090 |
Why?
| | Rats | 3 | 2006 | 4913 | 0.090 |
Why?
| | Cytostatic Agents | 1 | 2009 | 6 | 0.080 |
Why?
| | Butadienes | 1 | 2009 | 30 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 743 | 0.080 |
Why?
| | Enzyme Activation | 2 | 2009 | 771 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1014 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 438 | 0.080 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 181 | 0.080 |
Why?
| | Benzamides | 1 | 2009 | 168 | 0.080 |
Why?
| | Transfection | 4 | 2015 | 863 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 913 | 0.070 |
Why?
| | Indoles | 1 | 2009 | 300 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2764 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 212 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2009 | 192 | 0.070 |
Why?
| | Sulfonamides | 1 | 2009 | 444 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 295 | 0.070 |
Why?
| | Male | 5 | 2015 | 55396 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 742 | 0.060 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2783 | 0.050 |
Why?
| | Proteomics | 1 | 2009 | 815 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2008 | 2550 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2003 | 27 | 0.050 |
Why?
| | Neoplasms | 1 | 2016 | 2086 | 0.050 |
Why?
| | Transcription Factor Pit-1 | 2 | 2003 | 24 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2003 | 147 | 0.050 |
Why?
| | Protein Subunits | 1 | 2003 | 200 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 1981 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2003 | 337 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2002 | 181 | 0.050 |
Why?
| | Aged | 1 | 2019 | 18969 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2001 | 81 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1310 | 0.040 |
Why?
| | Oligonucleotides | 1 | 2001 | 137 | 0.040 |
Why?
| | Hypoxia | 1 | 2006 | 956 | 0.040 |
Why?
| | Pituitary Neoplasms | 1 | 2001 | 156 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 563 | 0.040 |
Why?
| | Toxicology | 1 | 2019 | 35 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 143 | 0.040 |
Why?
| | Middle Aged | 1 | 2019 | 26605 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 33 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 363 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.040 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 43 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.040 |
Why?
| | Oncogenes | 1 | 2018 | 104 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2018 | 241 | 0.040 |
Why?
| | Trans-Activators | 1 | 1999 | 366 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 170 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 131 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 289 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 476 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 1999 | 549 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 283 | 0.030 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 106 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2016 | 141 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 381 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2009 | 350 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1117 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2016 | 149 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1162 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 52 | 0.030 |
Why?
| | Microsatellite Repeats | 1 | 2014 | 137 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 528 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 463 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 80 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 88 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1350 | 0.030 |
Why?
| | Autophagy | 1 | 2014 | 235 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2371 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1469 | 0.020 |
Why?
| | Cell Movement | 1 | 2015 | 863 | 0.020 |
Why?
| | Oleanolic Acid | 1 | 2010 | 9 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3315 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 673 | 0.020 |
Why?
| | Sulfones | 1 | 2010 | 97 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2009 | 95 | 0.020 |
Why?
| | Serum | 1 | 2009 | 57 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 924 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1143 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2009 | 428 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2009 | 293 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 3861 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9049 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2464 | 0.010 |
Why?
| | Suppression, Genetic | 1 | 2003 | 23 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 93 | 0.010 |
Why?
| | Cell Extracts | 1 | 2002 | 15 | 0.010 |
Why?
| | Allosteric Regulation | 1 | 2002 | 81 | 0.010 |
Why?
| | United States | 1 | 2018 | 12137 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 507 | 0.010 |
Why?
| | Cell-Free System | 1 | 1999 | 47 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 1999 | 53 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 2002 | 670 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2114 | 0.010 |
Why?
| | Time Factors | 1 | 2002 | 6077 | 0.010 |
Why?
|
|
Schweppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|